Solventum Co. (NYSE:SOLV) Shares Acquired by Norinchukin Bank The

Norinchukin Bank The raised its holdings in shares of Solventum Co. (NYSE:SOLV) by 10.4% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 6,357 shares of the company’s stock after purchasing an additional 599 shares during the quarter. Norinchukin Bank The’s holdings in Solventum were worth $420,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of SOLV. Norges Bank acquired a new position in shares of Solventum in the 4th quarter worth $203,740,000. Boston Partners purchased a new position in Solventum in the 4th quarter worth about $110,378,000. Independent Franchise Partners LLP raised its holdings in Solventum by 105.0% during the 4th quarter. Independent Franchise Partners LLP now owns 1,603,154 shares of the company’s stock worth $105,904,000 after buying an additional 821,272 shares during the period. Nordea Investment Management AB lifted its stake in Solventum by 189.5% during the fourth quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock valued at $43,902,000 after buying an additional 431,986 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in shares of Solventum by 41.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,193,361 shares of the company’s stock worth $78,833,000 after buying an additional 347,669 shares during the period.

Solventum Stock Up 1.7 %

Shares of Solventum stock opened at $65.02 on Wednesday. The stock has a 50-day simple moving average of $73.04 and a 200-day simple moving average of $71.60. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $85.92. The firm has a market cap of $11.25 billion and a price-to-earnings ratio of 23.64. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Bank of America upped their price target on shares of Solventum from $80.00 to $85.00 and gave the company a “neutral” rating in a research report on Wednesday, February 26th. Mizuho raised their target price on Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, March 3rd. The Goldman Sachs Group upped their price target on Solventum from $63.00 to $71.00 and gave the company a “sell” rating in a research report on Monday, March 3rd. Piper Sandler raised their price objective on Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research report on Friday, February 28th. Finally, Morgan Stanley upped their target price on Solventum from $73.00 to $80.00 and gave the company an “equal weight” rating in a report on Wednesday, March 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $79.86.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.